Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,900
Closed -$4.19M 193
2025
Q4
$4.19M Buy
3,900
+3,700
+1,850% +$3.54M 0.21% 22
2025
Q3
$153K Buy
+200
New +$149K 0.02% 91
2023
Q1
Sell
-1,900
Closed -$695K 96
2022
Q4
$695K Sell
1,900
-10,200
-84% -$3.62M 0.08% 27
2022
Q3
$3.91M Buy
12,100
+300
+3% +$95K 0.32% 47
2022
Q2
$3.83M Sell
11,800
-17,700
-60% -$5.31M 0.28% 44
2022
Q1
$8.45M Buy
+29,500
New +$7.59M 0.32% 58
2021
Q4
Sell
-13,100
Closed -$3.03M 170
2021
Q3
$3.03M Buy
13,100
+6,300
+93% +$1.55M 0.2% 62
2021
Q2
$1.56M Buy
6,800
+4,800
+240% +$964K 0.16% 73
2021
Q1
$373K Buy
2,000
+1,000
+100% +$196K 0.03% 76
2020
Q4
$170K Buy
+1,000
New +$149K 0.02% 73

Other funds holding LLY

QVR's LLY Position: Q1 2026 in Review

QVR sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 7,177 shares — an estimated $7.28M sold.

QVR first reported a position in LLY in Q2 2021 and held it in 6 quarters. The position peaked at $7.71M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • QVR reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • QVR sold 7,177 Eli Lilly shares in Q1 2026, an estimated $7.28M.
  • QVR first reported a position in Eli Lilly in Q2 2021 and held it in 6 quarters.
  • QVR's Eli Lilly position peaked at $7.71M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on QVR's 13F filing for Q1 2026, filed 15 Apr 2026.